ALTSTATION.IO

Healthpeak Properties, Inc. (DOC) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$16.70

Change

+0.12%

Market Cap

$11.61B

Avg Volume

8.3M

Company Overview

Healthpeak Properties, Inc. is a real estate investment trust (REIT) focused on the healthcare sector, headquartered in Denver, Colorado. They specialize in owning, operating, and developing real estate primarily related to outpatient medical facilities, laboratories, and continuing care retirement communities (CCRCs). Their clients range from healthcare providers to seniors in need of long-term care. As of September 30, 2025, Healthpeak owns interests in 703 properties, including 530 outpatient medical facilities, 139 labs, and 15 CCRCs.

In the competitive landscape, Healthpeak is a significant player but not necessarily a market leader. Key competitors include Welltower Inc. and Ventas, Inc., both of which have more extensive portfolios. What gives Healthpeak an edge is its diverse range of properties and focus on high-quality healthcare facilities, which are in demand due to an aging population. However, the company faces risks such as changing regulations and occupancy rates in senior housing, which can impact revenues.

Currently, Healthpeak is in a phase of cautious growth, adapting to market changes. They’ve made recent strategic shifts to streamline their operations and focus on high-demand sectors, particularly outpatient medical facilities. This pivot aligns with broader industry trends towards outpatient care and preventative health services. Their portfolio’s diversification should position them well against market fluctuations as they continue to explore opportunities in healthcare real estate development.

Key Financials

Market Cap

$11.61B

Revenue

$2.82B

EBITDA

$1.56B

Gross Margin

60.0%

Profit Margin

2.5%

Revenue Growth

3.1%

Total Cash

$473.08M

Total Debt

$10.14B

Free Cash Flow

$1.16B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

167.00

Forward P/E

79.52

Beta

1.11

52-Week High

$21.28

52-Week Low

$15.71

EPS

$0.10

50-Day Avg

$16.98

200-Day Avg

$17.63

Price/Book

1.55

Technical Analysis

Over the past 52 weeks, Healthpeak Properties, Inc. (DOC) has shown a bearish trend, declining from a high of approximately $20 in February to its current price of $16.70, reflecting a decrease of 7.5%. Key resistance is identified around the $18 mark, where the stock has struggled to maintain momentum, while support is evident near the $16 level, suggesting a potential floor for the stock. The price patterns indicate multiple oscillations with higher volatility in the first half of the year, followed by a well-defined downtrend as visualized by the green trendline. Recently, the stock has displayed weak momentum, oscillating close to the $16.85 level, which is slightly above the current price, indicating indecision in the market. Currently, at $16.70, the stock sits firmly within its 52-week range, which spans from around $15 to $20, implying potential for either a rebound if support holds or further declines if selling pressure intensifies.

Recent News and Developments

Here’s a summary of the latest news and developments for Healthpeak Properties, Inc

(DOC) stock from January 31, 2026, to February 7, 2026:

1. Healthpeak Announces Plans for Senior Housing REIT Spin-off and Q4 2025 Results

Healthpeak Properties announced on February 2, 2026, its plan to launch Janus Living, Inc., a dedicated senior housing real estate investment trust (REIT), through an initial public offering (IPO) expected in the first half of 2026. This move is intended to unlock value for its senior housing portfolio, which Healthpeak believes the public markets have undervalued within the company. Concurrently, the company reported its fourth-quarter 2025 results, with diluted earnings per share of $0.16, missing the consensus estimate of $0.45, but revenue of $719.40 million surpassed analyst estimates of $685.14 million. For the full year 2026, Healthpeak provided guidance for diluted earnings per common share between $0.34 and $0.38, and diluted Nareit FFO per share of $1.70 to $1.74.

2. Analyst Downgrade Amidst Lab Market Concerns

On December 15, 2025 (relevant as it falls within the recent analyst activity impacting sentiment), Jefferies downgraded Healthpeak Properties Inc. from “Buy” to “Hold” and reduced its price target to $17.00 from $21.00. This downgrade was primarily driven by concerns regarding weak laboratory market fundamentals, including rising vacancy rates in key markets and a decline in trailing twelve-month biotech funding. While acknowledging Healthpeak’s strategy to increase lab exposure, Jefferies expressed concerns about execution risks and anticipated a challenging year for the laboratory sector in 2026. More recently, on February 2, 2026, Wells Fargo & Company also lowered its price target for Healthpeak Properties from $19.00 to $18.00, maintaining an “equal weight” rating.

Market Sentiment and Analyst Recommendations

Bull Case

The Janus Living IPO planned for H1 2026 is the real story here. Healthpeak believes its senior housing portfolio is undervalued within the conglomerate structure, and a dedicated REIT could unlock significant value for shareholders. The company is also doubling down on life sciences with the $600 million Gateway Boulevard acquisition in South San Francisco, expanding its biopharma footprint to 6.5 million square feet across 210 acres in a tight, high-demand submarket. Management’s 2026 FFO guidance of $1.70-$1.74 per share paired with a monthly dividend of $0.10167 ($1.22 annualized) provides 7.3% yield at current prices, which is attractive for income investors. The $925 million in capital recycling activity shows disciplined asset management and capital allocation. At 167x P/E, the valuation is inflated, but that’s a red herring for REITs — FFO multiples matter more, and the forward yield is legitimate. Analyst consensus sits at $19.88 target, implying 19% upside from $16.70.

Bear Case

That Q4 EPS miss is ugly. Healthpeak posted $0.16 diluted EPS versus the $0.45 consensus estimate, a 64% miss that signals operational headwinds or one-time charges. Jefferies downgraded in December citing weak lab market fundamentals, rising vacancy rates, and declining biotech funding — exactly the sectors Healthpeak is betting on. The company carries $10.14 billion in debt against only $473 million in cash, a leverage ratio that leaves little room for error if cap rates widen or occupancy deteriorates. The stock is down 15.91% over the past year and stuck oscillating near $16.85 with weak momentum, suggesting the market isn’t convinced by the turnaround narrative yet. Lab vacancy is rising in key markets, which directly threatens the value of that $600 million Gateway acquisition. The Janus spin-off is a catalyst, but it’s also an admission that Healthpeak couldn’t maximize senior housing value on its own — execution risk is real.

What to Watch

The Janus Living IPO launch timeline and pricing will be the defining catalyst. If the IPO happens in H1 2026 and prices above expectations, it validates management’s unlock thesis and could re-rate the parent company. Monitor Q1 2026 earnings for occupancy trends in the lab portfolio, especially in South San Francisco and other key biopharma markets — rising vacancy rates would confirm Jefferies’ concerns and pressure the stock further. Watch the 2026 FFO guidance execution closely. If Healthpeak hits the $1.70-$1.74 range, the 7.3% yield becomes defensible; if they miss, dividend risk rises. Track biotech funding data and venture capital deployment rates as leading indicators for lab demand. The stock needs to break above $18 resistance to signal momentum recovery; failure to hold $16 support suggests further downside to $15. Finally, monitor analyst revisions post-Jefferies downgrade. If more analysts follow Wells Fargo’s lead and cut targets, that’s a sign institutional conviction is deteriorating.

Analyst Consensus

BUY

Based on 17 analyst opinions

Low Target

$16.00

Mean Target

$19.88

High Target

$29.00

Earnings and Financial Data

Sector

Real Estate

Industry

REIT – Healthcare Facilities

Employees

411

Earnings & Dividends

Next Earnings

Apr 23, 2026

EPS (Trailing)

$0.10

Dividend Yield

731.0%

Payout Ratio

1220.0%

Frequently Asked Questions

Is DOC a good stock to buy?

Yes, Healthpeak Properties, Inc. (DOC) currently has a BUY recommendation from analysts with a target price of $19.88. Given its 52-week range of $15.71 – $21.28, there’s potential for price appreciation.

What is DOC’s price target?

The analyst price target for DOC is $19.88. This suggests approximately a 19.5% upside from its current price of $16.70.

Does DOC pay a dividend?

Yes, DOC has a hefty dividend yield of 731.0%. This makes it an attractive option for income-focused investors, although it’s important to dig deeper into sustainability.

What is the P/E ratio for DOC?

Healthpeak Properties has a P/E ratio of 167.00 and a forward P/E of 79.52. These high ratios indicate that investors might be expecting strong future growth, but it also raises concerns about valuation.

What market cap does DOC have?

Healthpeak Properties has a market cap of $11.61 billion. This positions it as a significant player in the healthcare REIT sector, providing stability and potential growth in the long term.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.